KRMDHealthcare · Medical Instruments & SuppliesThe 5 Wall Street analysts covering KORU Medical Systems, Inc. hold a median 12-month price target of $7 — +65.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 95 of 100 as at 1 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores KORU Medical Systems, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (93): The business earns solid, repeatable profits on what it owns.
Revisions (57): Analysts have, on balance, been cutting their forecasts.
The rank is the raw material. Whether the rules would actually own KORU Medical Systems, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on KRMD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +65.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Mar 2026 | B. Riley Securities | Maintains | Buy | $7.00 → $8.00 |
| 13 Mar 2026 | Canaccord Genuity | Maintains | Buy | $6.00 |
| 22 Dec 2025 | Lake Street | Maintains | Buy | — |
| 17 Dec 2025 | Canaccord Genuity | Maintains | Buy | — |
| 7 Aug 2025 | Piper Sandler | Maintains | Neutral | — |
| 8 May 2025 | Piper Sandler | Maintains | Neutral | — |
| 14 Feb 2025 | Piper Sandler | Downgrade | Neutral | — |
| 17 Jan 2025 | Craig-Hallum | Maintains | Buy | — |
| 14 Jan 2025 | Lake Street | Maintains | Buy | — |
| 14 Nov 2024 | Canaccord Genuity | Maintains | Buy | — |
| 14 Nov 2024 | Craig-Hallum | Maintains | Buy | — |
| 14 Nov 2024 | Piper Sandler | Maintains | Overweight | — |
| 8 Aug 2024 | Piper Sandler | Maintains | Overweight | — |
| 14 Mar 2024 | B. Riley Securities | Reiterates | Buy | — |
| 7 Dec 2023 | Canaccord Genuity | Reiterates | Buy | — |
| 7 Sept 2023 | B. Riley Securities | Initiates | Buy | — |
| 7 Sept 2023 | Lake Street | Initiates | Buy | — |
| 3 Aug 2023 | Piper Sandler | Maintains | Overweight | — |
| 6 Jan 2023 | Piper Sandler | Maintains | Overweight | — |
| 10 Nov 2022 | Canaccord Genuity | Upgrade | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 99% of US stocks
Cheaper than 28% of US stocks
Cheaper than 9% of US stocks
Cheaper than 96% of US stocks
Higher than 74% of US stocks
Higher than 64% of US stocks
Higher than 76% of US stocks
Higher than 28% of US stocks
Higher than 23% of US stocks
Higher than 34% of US stocks
Higher than 31% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KRMD appears on the weeks it earns a place.
KORU Medical Systems announced that its management team will participate in and present at the Canaccord Genuity 46th Annual Growth Conference on August 12th, 2026.
Why it matters — Conference participation gives KORU Medical an opportunity to present its business and large-volume subcutaneous infusion technology to the investment community.
The 5 Wall Street analysts covering KORU Medical Systems, Inc. have a median 12-month price target of $7, with estimates ranging from $5 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering KORU Medical Systems, Inc., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks KORU Medical Systems, Inc. 95 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, KORU Medical Systems, Inc. ranks 95 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (93 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +65.5% from the last close, and Ticker Nerd's factor model ranks KORU Medical Systems, Inc. 95 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering KORU Medical Systems, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KRMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $8 over the next 12 months.
KORU Medical Systems, Inc. returned +21.6% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Koru Medical Systems Inc. is a medical device company that develops, manufactures, and commercializes subcutaneous infusion solutions for the subcutaneous drug delivery market in the United States and internationally.
The most recent item we track (Business Wire, 29 July 2026): "KORU Medical Systems to Participate in the Canaccord Genuity 46th Annual Growth Conference". KORU Medical Systems announced that its management team will participate in and present at the Canaccord Genuity 46th Annual Growth Conference on August 12th, 2026.
Koru Medical Systems Inc. is a medical device company that develops, manufactures, and commercializes subcutaneous infusion solutions for the subcutaneous drug delivery market in the United States and internationally. The company specializes in home and specialty infusion solutions, with a primary focus on its FREEDOM Infusion Systems, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. These devices deliver life-saving therapies to patients with chronic illnesses such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, secondary immunodeficiency disorder, and paroxysmal nocturnal hemoglobinuria. Operating at lower pressure than traditional electrical pumps, the systems balance patient tissue tolerance with accurate delivery in home care, alternate settings, emergency care, hospitals, nursing homes, and other medical facilities. Founded in 1980 and headquartered in Mahwah, New Jersey, Koru Medical Systems Inc. serves healthcare providers and patients emphasizing responsive problem-solving and patient experience in the healthcare equipment sector.
CEO Mr. Adam Kalbermatten · 73 employees · United States · https://www.korumedical.com